CD274 and hepatocellular carcinoma: These inhibitors, such as programmed death-1 (PD-1) or programmed cell death 1 ligand 1 (PD-L1) inhibitors, have exhibited significant efficacy in a specific subset of HCC patients characterized by distinct molecular features (8).